Background: Total thyroidectomy is increasingly being adopted for patients requiring surgical treatment for Graves' disease based on a comparable surgical risk and the lack of recurrence, as well as the questionable ability of subtotal thyroidectomy to maintain euthyroidism. The purpose of the present paper was to evaluate its safety and efficiency. Methods: Total thyroidectomy was adopted as part of the routine surgical treatment for Graves' disease from 2000. Patients who underwent subtotal thyroidectomy (STT) from 1995 to 1999 ( n = 119) were compared with those who underwent total thyroidectomy (TT) from 2000 to 2003 ( n = 98) with respect to immediate postoperative morbidity and long-term outcome. Results: Fourteen (11.8%) and 22 patients (22.4%) required calcium supplement on discharge in the STT and TT groups, respectively ( P < 0.05). One (0.8%) and three patients (3.1%) developed permanent hypocalcaemia, respectively. Transient recurrent laryngeal nerve palsy occurred in 9.2% ( n = 11) and 5.1% ( n = 5) of patients or 5.0% and 2.6% of nerves at risk after STT and TT, respectively. None of the patients had permanent nerve palsy. The estimated blood loss was less and hospital stay shorter after TT. During a mean follow up of 64 months, 86 patients (72.3%) in the STT group required thyroxine replacement and seven patients (5.9%) developed relapse. Conclusion: Subtotal thyroidectomy was associated with relapse as well as hypothyroidism in a significant proportion of patients during long-term follow up. Total thyroidectomy can be performed as safely as STT and should be recommended as the procedure of choice for patients requiring surgical treatment for Graves' disease.
INTRODUCTION
Graves' disease can be treated by antithyroid medication, radioactive iodine and surgery. When surgical treatment is indicated or selected for patients with Graves' disease, bilateral subtotal thyroidectomy (STT) has been recommended as the standard surgical procedure. The goal of STT is to obtain rapid control of thyroid function by removing the pathological gland and leaving a small remnant of thyroid tissue to maintain adequate hormone production, while being a relatively safe operation with low complication rates. However, recurrent hyperthyroidism from the remnant thyroid tissues occurs during longterm follow up. From the 1960s, a group of surgeons began to adopt a more radical approach to treat Graves' disease by total thyroidectomy (TT) in order to eliminate recurrence while maintaining an acceptable complication rate. 1 Since then, the surgical strategy adopted for Graves' disease has become a controversial issue, with an increasing number of endocrine surgeons performing total instead of subtotal thyroidectomy. The aim of the present study was to evaluate the safety of employing TT instead of STT as the procedure of choice for patients requiring surgical treatment for Graves' disease at Queen Mary Hospital, the University of Hong Kong, by adopting a standard operative strategy as well as perioperative care over a consecutive time period. Patients who underwent surgical treatment by STT were compared with those undergoing TT with reference to the occurrence of postoperative morbidity and the functional outcome during long-term follow up.
METHOD
Graves' disease was diagnosed based on the clinical presentation of thyrotoxicosis, usually in the presence of a diffuse goitre with or without thyroid eye signs. It was confirmed by hormonal and/ or immunologic assays. Radioscintigraphy would be performed for selected patients in the case of diagnostic difficulty. Antithyroid medications were prescribed to patients routinely to achieve euthyroidism and, in addition, beta-blocker was added for symptomatic control. Lugol's iodine was not administered.
Subtotal thyroidectomy was traditionally adopted as the procedure of choice at our institution in the belief that long-term euthyroidism can be achieved and that complication rates may be potentially increased with TT. During STT, an estimated thyroid remnant of up to 2-3 g was left on each thyroid lobe. Since 2000, total thyroidectomy became the procedure of choice and only five STT were performed due to patient wishes. Patients who underwent near-total thyroidectomy with a remnant of <1 g based on intraoperative decision were analysed in the TT group. During thyroidectomy for Graves' disease, bilateral recurrent laryngeal nerves were routinely identified and preserved. Routine perioperative laryngoscopy was performed within 1 week before and after the operations. All patients found to have recurrent laryngeal nerve palsy after the operations were referred to otorhinolaryngologist specialists for assessment and speech therapy. Repeated laryngoscopes were performed at regular intervals during follow up and permanent nerve palsy was defined as persistent palsy for >12 months after operation. Identification of all parathyroid glands was attempted but extensive dissection was avoided. Parathyroid preservation in situ by meticulous dissection was adopted, but inadvertently removed or unequivocally devascularized parathyroid glands were removed routinely for immediate autotransplantation into the neck muscle. 2, 3 Routine measurement of serum calcium was performed within 6 h of surgery and at least once daily until stabilization during hospital stay. Replacement with calcium and/or vitamin D analogue was given when serum calcium level was <1.70 mmol/ L (normal 2.1-2.55 mmol/L) or when hypocalcaemia symptoms developed. Those who could discontinue the calcium and vitamin D analogue supplement in the presence of normocalcaemia within 12 months after operation were classified as having temporary hypocalcaemia. Permanent hypocalcaemia was defined as the requirement of calcium supplement for >12 months during follow up and was associated with a subnormal serum parathyroid hormone level (normal, 11-54 pg/mL).
Routine measurement of serum free thyroxine (T 4 ) and thyroid stimulating hormone (TSH) levels were done in all patients at 3-6-monthly interval for 2 years and then at 6-12-monthly intervals subsequently during follow-up visits. Patients with two consecutive subnormal T 4 (normal 12-23 pmol/L) and/or elevated TSH (normal 0.35-5-5 mIU/L) levels during follow-up blood tests were regarded as having postoperative hypothyroidism and thyroxine replacement would be prescribed. Postoperative or recurrent hyperthyroidism was defined as persistently elevated T 4 or suppressed TSH requiring additional treatment during follow up.
Data for all patients undergoing thyroidectomy by one endocrine surgical unit were prospectively entered into a thyroid database from 1995 and all patients surgically treated for Graves' disease up to June 2003 were retrospectively reviewed. Patients who had history of partial thyroidectomy prior to the present operation were excluded. Complete follow-up data with respect to postoperative hypothyroidisim and recurrence were retrieved and all patients had a minimum follow up of 6 months. Patients who underwent STT were compared with those who underwent TT with respect to demographics, operative details, postoperative complications and long-term outcome.
Statistical analysis was performed with Student's t -test (continuous variables) and χ 2 or Fischer's exact test when relevant (categorical variables). Recurrence was estimated using the Kaplan-Meier estimation method. P < 0.05 was regarded as statistically significant.
RESULTS
There were 119 and 98 patients in the STT and TT groups, respectively. Patients in both groups were comparable with reference to gender, weight of thyroid tissue resected and operative time except that patients who underwent TT (mean age ± SD: 34.7 ± 24.8 years) were older than those who underwent STT (27.9 ± 13.8 years; P < 0.001). Patients who underwent TT had significantly less estimated blood loss (100.6 ± 268.6 mL vs 202.1 ± 489.4 mL; P < 0.001) during the operations compared with those who underwent STT. The hospital stay for patients who underwent TT (3.2 ± 2.4 days) was significantly shorter compared to those who underwent STT (4.2 ± 3.0 days; P < 0.001; Table 1 ). Eleven (9.2%) and five patients (5.1%) in the STT and TT groups, respectively, developed transient vocal cord palsy after the operations. One patient in the STT group was found to have bilateral cord palsy during routine laryngoscopy. However, the airway was adequate and tracheostomy was not required. Bilateral cord function recovered spontaneously within 3 months after the operation. There was no permanent recurrent laryngeal nerve palsy in all patients and vocal cord function recovered over a mean duration of 3.6 months (range, 1-8 months) after the operations. The incidence of transient recurrent nerve palsy according to the number of nerves at risk was calculated to be 5.0% (12/ 238) and 2.6% (5/196) for the STT and TT group, respectively. The difference in the incidence of nerve palsy between STT and TT was not statistically significant.
In contrast, the incidence of postoperative hypocalcaemia was significantly higher for patients who underwent TT compared to those who underwent STT ( P = 0.044). Fourteen of 119 (11.8%) compared with 22 of 98 patients (22.4%) in the STT and TT group, respectively, developed hypocalcaemia in the postoperative period. During follow up, one of 119 patients (0.8%) had persistent hypocalcaemia in the STT group compared with three of 98 patients (3.1%) in the TT group and the incidence of permanent hypoparathyroidisim was not statistically different between these two groups ( Table 2) .
During a mean follow up of 65 months (range 6-104 months), 86 patients (72.3%) in the STT group developed postoperative hypothyroidism and required thyroxine replacement. All patients in the TT group received thyroxine replacement on discharge and remained dependent on thyroxine to maintain euthyroid status during follow up. Seven patients (5.9%) in the STT group developed recurrence within 10-60 months (mean 36 months). The recurrent hyperthyroidism rates were 2.6% and 6.0% at 3 and 5 years, respectively (Fig. 1) . For the seven patients having recurrence after STT, five received radioactive iodine ablation; one, completion thyroidectomy; and one, medical treatment.
DISCUSSION
The goal of treating Graves' disease is to control hyperthyroidism and to restore euthyroidism. There are three major treatment modalities available for Graves' disease, and each option has its advantages as well as potential problems or side-effects. Surgery has been the main treatment option in the past, until the mid-20th century when antithyroid medications and radioactive iodine became available. In addition, there has been a great geographical difference in the adoption of different treatment modalities for Graves' disease. Radioactive iodine ablation is now the preferred treatment in North America, while European physicians favour antithyroid medication. 4 Surgery remains indicated for selected patients with nodules suspicious for malignancy, large goitre in the presence of compressive symptoms, requiring rapid control, planning for pregnancy, who fear radioactive treatment, with poor compliance and often for those who develop side-effects or recurrence after antithyroid medication. 5 Subtotal thyroidectomy has been the gold standard for patients requiring surgical treatment for Graves' disease. It is believed that by leaving a small remnant of functioning gland, euthyroidism can be achieved without the need for lifelong thyroxine replacement. In addition, limited dissection is performed in the tracheo-oesophageal grooves with minimal potential risk of damaging the recurrent laryngeal nerves as well as the parathyroid glands. Therefore, it is thought to be a safer operation compared to TT with respect to postoperative recurrent laryngeal nerve palsy and hypoparathyroidism. However, this concept is being challenged by the excellent results achieved by an increasing number of endocrine surgeons who are adopting TT as the surgical treatment of choice for Graves' disease. [6] [7] [8] [9] Total thyroidectomy for benign thyroid disease is likely to become an accepted component of the endocrine surgeon's armamentarium. 10 The only randomized control trial comparing TT and STT showed a significant difference in the incidence of transient hypoparathyroidism rate of 12% versus 28% in favour of STT. In addition, there was a tendency toward a higher permanent hypoparathyroidism in the TT group (6% vs 10%, P = 0.06). 11 In a meta-analysis by Palit et al . on >7000 patients treated with either TT or STT, there was no statistical difference with respect to the incidence of two major complications, namely hypoparathyroidism and recurrent laryngeal nerve injury. 12 Although we demonstrated a statistically significant difference in the incidence of transient hypoparathyroidism rate that favours STT, there was neither any significant difference in the incidence of permanent hypoparathyroidism nor recurrent laryngeal nerve injury. For patients who underwent TT, the estimated blood loss and hospital stay were significantly less compared with those who underwent STT. Apart from the change in operative strategies, the difference in these outcome results can be partly attributed to the improvement in patient care.
In addition, contrary to the belief that STT is associated with additional advantage of achieving euthyroidism compared with TT, thyroid dysfunction is not uncommon after STT. A significant proportion of patients become hypothyroid during long-term follow up after STT, and postoperative hypothyroidism ranges from 4% to 75% in various reported series. [13] [14] [15] [16] [17] [18] [19] [20] In addition, it is not infrequent for recurrent hyperthyroidism to occur after STT and up to 20% of patients develop recurrence during long-term follow up. 21 The majority of patients requiring surgical treatment have either rejected or have relative contraindications for other treatment modalities. Recurrent hyperthyroidism forces these patients back to other previously declined treatment modalities or subjects patients to reoperations that carry a considerable surgical risk. 22, 23 Different factors including the size of the thyroid remnant, the presence of thyroid-stimulating hormone binding inhibitory immunoglobulin, antimicrosomal antibodies or antithyroglobulin antibodies, and the degree of lymphoid infiltration in the thyroid gland have been studied to predict thyroid function after surgery. The size of the remnant remains the most consistent predictive factor for postoperative thyroid function with respect to both hypothyroidism and recurrent hyperthyroidism. 8, 16 Palit et al . in their meta-analysis showed that remnant size was negatively correlated with hypothyroidism, with an 8.9% decline in the rate of hypothyroidism for each gram of thyroid remnant left. 12 Euthyroidism was also positively and significantly correlated with remnant size, with a 6.9% increase in the rate of hyperthyroidism per additional gram of thyroid remnant left. The chance of hypothyroidism becomes lower if more thyroid tissue is left behind, but the risk of recurrent hyperthyroidism becomes substantial. However, in retaining less thyroid tissue to reduce the chance of recurrent hyperthyroidism, it will be associated with a higher risk of hypothyroidism. There is no consensus on how much thyroid tissue should be left behind and it is reflected by the large variation in postoperative thyroid status after STT. In the end, a small proportion of patients can achieve euthyroidism at the expense of a significant number of patients developing either hypothyroidism or hyperthyroidism.
In addition, the definition of hypothyroidism or hyperthyroidism affects the reported incidence of postoperative thyroid function. Some argue that latent hypothyroidism (normal T 4 /T 3 levels with elevated TSH level) or latent hyperthyroidism (normal T 4 /T 3 with suppressed TSH) are subclinical problems and should be counted as normal and reported as euthyroidism, while others count those as the abnormal group. The great variation in the duration of follow up also contributes to the different results among various studies. With a longer follow-up period, more patients with abnormal thyroid function will be detected. Dominello et al . showed a progressive onset of both hypothyroidism and recurrent hyperthyroidism with time. 14 The proportion of patients with hypothyroidism increased from 48.5% at 6 months to 69.3% at 15 years after STT. 14 In addition, instability of thyroid function is a common phenomenon after STT, and a significant proportion of patients cannot achieve euthyroidism after STT. 14, 18, 24 For those who are euthyroid in the early postoperative period after STT, they still have a continuous risk of developing abnormal thyroid function. Therefore, long-term monitoring of thyroid function is required. In contrast, thyroid function is more predictable after TT and can be easily maintained with thyroxine replacement. In fact, hypothyroidism should be regarded as an end-point of surgical treatment rather than a complication of total thyroidectomy. In the present study a 72.3% incidence of hypothyroidism after STT seems to be relatively high compared to other studies. However, it can be explained by the inclusion of latent or subclinical hypothyroidism as well as a relatively long follow-up period. Furthermore, recurrent hyperthyroidism developed in 5.9% of patients. As a result, only 21.8% of patients remained euthyroid after STT.
In conclusion, despite the adoption of STT as the surgical treatment for Graves' disease, apart from the substantial rate of recurrence, a significant number of patients developed hypothyroidism and required long-term thyroxine replacement. In experience hands, TT has been shown to be as safe as STT for surgical treatment of Graves' disease with respect to the postoperative complication rate. However, it can provide a much more predictable thyroid function outcome immediately after surgical treatment and during long-term follow up with thyroxine replacement. Therefore, TT has replaced STT as the procedure of choice for patients requiring surgical treatment for Graves' disease.
